Developer docs
API playgroundTry for free, no card

Search company profiles

NeuraMetrix

Full company profile

uuid000h8vc

Namestring
NeuraMetrix
Legal namestring
NeuraMetrix, Inc.
Websiteurl
neurametrix.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

NeuraMetrix, Inc. is a private medical device company headquartered in Asheville, North Carolina, operating with a distributed team of approximately ten members across the United States, Europe, and Asia. Originally incorporated in 2012 as a behavioral-biometrics company focused on password elimination via typing cadence, the company pivoted in 2017-2018 to neurotechnology after Dr. Robert W. Mahley of the Gladstone Institutes recognized the potential of keystroke timing patterns for neurological disease detection. Its flagship platform, NeuraMetrix TC, is a passive digital biomarker that measures typing cadence — dwell times and flight times — running in the background on a patient's own Windows PC without active participation. Raw keystroke data is processed locally to remove identifying information, batched in 1,000-keystroke windows (often totaling ~10,000 keystrokes per day), and uploaded to NeuraMetrix's secure cloud servers where the proprietary SINCOR algorithm calculates inconsistency scores that serve as a quantitative brain-health metric.

The product is delivered as three integrated components: the NeuraMetrix TC Application (passive desktop client), the NeuraMetrix Server (cloud analytics), and the NeuraMetrix Online Dashboard (clinician/researcher portal). The company holds FDA Breakthrough Device Designation for Parkinson's Disease (January 2019), though it is not yet FDA cleared or CE-marked, and has been granted patents in the US, Australia, and Japan covering the methodology and system architecture.

The company monetizes through three primary channels: (1) software licensing to neurologists, psychiatrists, and clinical sites who prescribe the patient download, (2) contract-based pharma/biotech clinical-trial services for neurologic and psychiatric drug development, and (3) regional revenue-sharing or licensing via channel partners — bioaccess for Latin America and N-Strategy Consulting Services for Asia-Pacific. Pricing is enterprise-negotiated and not publicly disclosed. Research validation is conducted with a global network of academic institutions including Boston University, Karolinska Institutet, Huntington Center Ulm, UCSF, Mayo Clinic, Lund University, Uppsala University, University of Toronto, Dutch University Medical Centers, and others.

Short descriptiontext

NeuraMetrix is a private medical device company that has developed a passive digital biomarker platform measuring typing cadence on a personal computer to detect and monitor neurological diseases and psychiatric disorders, serving physicians, patients, pharmaceutical trial sponsors, and academic researchers; it holds FDA Breakthrough Device designation for Parkinson's Disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAsheville, United States
HQ citystring
Asheville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital biomarker software, typing cadence analysis, neurological disease monitoring, cognitive function assessment, passive brain health tracking
Industry1 code
PRIMARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Other Computer Related Services541519
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Health / Digital Biomarker Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Software Licensing (Physician/Clinic)
TypeSubscription Recurring
Description

NeuraMetrix TC software is prescribed/distributed by physicians and clinical trial teams to patients. The physician provides the software download link via email. The company generates revenue through software licensing to healthcare providers and clinical trial operators. Pricing is not publicly disclosed; billing is likely per-seat or subscription-based per patient or per physician/clinic.

neurametrix.com
2Pharma Drug Trial Services
TypeProfessional Services
Description

NeuraMetrix provides its digital biomarker for use in pharmaceutical clinical trials for neurological and psychiatric drug development. Pharma companies use the platform to monitor trial participants' cognitive and motor performance, enabling faster go/no-go decisions, reduced heterogeneity, and fewer dropouts. Revenue likely derived from study setup fees, per-subject licensing, and data analysis services.

neurametrix.com
3Regional Distribution Partnerships
TypeLicensing Royalties
Description

NeuraMetrix partners with regional distributors (bioaccess™ for Latin America, NSCS for Asia-Pacific) who commercialize the technology in their respective markets, likely through revenue-sharing or licensing arrangements.

neurametrix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

NeuraMetrix provides the NeuraMetrix TC platform, a passive digital biomarker that detects and monitors neurological diseases and psychiatric disorders by analyzing typing cadence (keystroke dwell and flight times) on a patient's own Windows PC or laptop. The platform comprises three components: the NeuraMetrix TC Application (passive client), the NeuraMetrix Server (cloud analytics computing the proprietary SINCOR inconsistency metric), and the NeuraMetrix Online Dashboard (visualization portal for clinicians and patients). It is sold primarily through physicians/clinics and clinical trial operators for remote, continuous brain health monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 65 million data points collected and analyzed in a single study (154 subjects, 90 days)
+4 more records
Product overview1 text field

NeuraMetrix offers a unified digital biomarker platform consisting of three integrated components: the NeuraMetrix TC Application (a passive desktop client for keystroke data collection), the NeuraMetrix Server (cloud-based analysis infrastructure running proprietary SINCOR algorithms), and the NeuraMetrix Online Dashboard (a web portal for clinicians, researchers, and patients to visualize inconsistency scores and disease progression trends). The platform measures typing cadence inconsistency as a digital biomarker for detecting and monitoring neurodegenerative diseases (Parkinson's, Huntington's, Alzheimer's) and psychiatric disorders (depression, bipolar disorder).

Product and service3 records
1NeuraMetrix TC Application
CategoryDigital Biomarker Software
Description

Passive desktop client software that runs in the background on a user's Windows PC or laptop, collecting keystroke timing data (dwell and flight times) whenever the keyboard is used. The software is downloaded via email link sent by a physician or clinical trial team, requires no active participation, and never stores typed content — only timing metadata.

2NeuraMetrix Server
CategoryCloud Analytics Platform
Description

Secure cloud-based server infrastructure that receives typing cadence data batches from the TC Application, performs outlier analysis, and computes the proprietary SINCOR (inconsistency) metric using patented algorithms.

3NeuraMetrix Online Dashboard
CategoryClinical Visualization Portal
Description

Web portal (portal.neurametrix.com) that visualizes the patient's SINCOR inconsistency score as a longitudinal line graph for healthcare providers, research institutions, and (when permitted) patients, enabling monitoring of brain health trends over time.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

Boston University School of Medicine selected NeuraMetrix's digital biomarker to participate in the Precision Brain Health Initiative, funded by the American Heart Association in collaboration with global philanthropist Bill Gates. NeuraMetrix is one of the selected technologies in this major brain health program. Active research programs include heart problems and dementia, with planned Alzheimer's studies.

2Huntington Center Ulm, Ulm University, Germany
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-04-08
Description

NeuraMetrix and Huntington Center Ulm (Department of Neurology, Ulm University, Germany) jointly published a peer-reviewed research article: 'Monitoring the Phenotype in Huntington Disease by Analysis of Keyboard Typing During Real Life Computer Use' in the Journal of Huntington's Disease. The study demonstrated that the digital biomarker can separate Huntington's mutation carriers with no visible symptoms into two groups: disease-not-yet-active and disease-has-already-begun.

neurametrix.com
3bioaccess™
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-27
Description

Orlando-based contract research organization (CRO) and market access consulting firm dedicated to helping innovative Medtech companies succeed with market expansion in Latin America. bioaccess™ and NeuraMetrix entered a partnership agreement to conduct clinical research and commercialize the digital brain health monitoring biomarker based on typing cadence in Latin America. This is a key channel partnership for NeuraMetrix to reach patients and healthcare providers in Latin American markets including Colombia.

neurametrix.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-07-23
Description

NSCS, founded by Nathanael Noiraud, with its founder and CEO, accelerates and invests in NeuraMetrix's Asia-Pacific market entry. NSCS provides market entry strategy, business development, and investment to establish NeuraMetrix in Malaysia and other Asia-Pacific markets.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2019-01-08
Description

NeuraMetrix showcased its technology at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, where the FDA Breakthrough Device designation was announced. The company has also been selected to present at McKinsey's Early-Stage Investor Conference (ESIC) in June 2022.

6SharpBrains (Brainnovations Competition)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2018-01-09
Description

NeuraMetrix won the SharpBrains Brainnovations competition (January 2018) for its innovative digital biomarker technology. The competition win provided visibility and recognition in the digital brain health ecosystem.

neurametrix.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

NeuraMetrix completed a landmark study with the Michael J. Fox Foundation's Fox Trial Finder program. 154 subjects were monitored for 90 days, collecting and analyzing 65 million data points. The study demonstrated the ability to distinguish diagnosed Parkinson's patients from healthy subjects and monitor disease progression, identifying patients whose variability was under control, out of control, and worsening.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Digital biomarker platform that uses cognitive and motor tasks on smartphones/tablets to predict and diagnose Alzheimer's and MCI. Directly comparable to NeuraMetrix as a digital neurological biomarker seeking FDA pathway and pharma trial adoption.

TypeDirect peer
Description

Provider of computerized cognitive assessments (e.g., CANTAB) widely used in pharma clinical trials and clinical research for neurological and psychiatric conditions. Comparable in serving pharma CNS trial sponsors with objective cognitive endpoints.

TypeDirect peer
Description

Digital biomarker company building a multi-modal at-home neurology platform for CNS clinical trials and clinical practice across conditions like depression and Alzheimer's. Closely comparable in modality (passive/remote measurement) and pharma trial positioning.

TypeDirect peer
Description

Digital cognitive assessment platform used by physicians and clinical researchers to detect and monitor cognitive impairment. Overlaps with NeuraMetrix in clinical decision support for neurology and in clinician-driven workflows.

TypeEmerging player
Description

Digital cognitive health company focused on early detection of dementia and other neurological conditions via tablet-based assessments. Adjacent emerging competitor targeting similar early-detection use cases in neurology practices.

TypeBroad incumbent
Description

Large-scale digital health measurement platform that captures continuous behavioral and physiological data from consented consumers for research and pharma. Comparable in mining passive digital signals for health insights, though broader in scope.

TypeBroad incumbent
Description

Public digital therapeutics company with FDA-cleared products for ADHD and other cognitive conditions. Comparable in pursuing prescription digital products for CNS indications, but delivers active treatment rather than passive monitoring.

TypeBroad incumbent
Description

Major clinical trial technology and imaging/biomarker vendor serving pharma CNS trials at scale. Comparable as a vendor competing for pharma digital-endpoint budgets, though with a much broader portfolio including imaging and eCOA.

TypeBroad incumbent
Description

Major pharma with Floodlight, a smartphone-based passive digital biomarker program for MS and other neurological diseases. Represents the kind of vertically integrated, well-capitalized competitor that can bundle digital biomarkers into its own drug commercialization.

TypeBroad incumbent
Description

Dominant clinical trial technology platform with expanding digital biomarker and sensor capabilities acquired through its ecosystem. Comparable as a platform-of-record for CNS pharma trials where NeuraMetrix seeks to be embedded.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuraMetrix

Digital Health / Digital Biomarker Softwareneurametrix.com

NeuraMetrix is a private medical device company that has developed a passive digital biomarker platform measuring typing cadence on a personal computer to detect and monitor neurological diseases and psychiatric disorders, serving physicians, patients, pharmaceutical trial sponsors, and academic researchers; it holds FDA Breakthrough Device designation for Parkinson's Disease.

What NeuraMetrix does

NeuraMetrix, Inc. is a private medical device company headquartered in Asheville, North Carolina, operating with a distributed team of approximately ten members across the United States, Europe, and Asia. Originally incorporated in 2012 as a behavioral-biometrics company focused on password elimination via typing cadence, the company pivoted in 2017-2018 to neurotechnology after Dr. Robert W. Mahley of the Gladstone Institutes recognized the potential of keystroke timing patterns for neurological disease detection. Its flagship platform, NeuraMetrix TC, is a passive digital biomarker that measures typing cadence — dwell times and flight times — running in the background on a patient's own Windows PC without active participation. Raw keystroke data is processed locally to remove identifying information, batched in 1,000-keystroke windows (often totaling ~10,000 keystrokes per day), and uploaded to NeuraMetrix's secure cloud servers where the proprietary SINCOR algorithm calculates inconsistency scores that serve as a quantitative brain-health metric.

The product is delivered as three integrated components: the NeuraMetrix TC Application (passive desktop client), the NeuraMetrix Server (cloud analytics), and the NeuraMetrix Online Dashboard (clinician/researcher portal). The company holds FDA Breakthrough Device Designation for Parkinson's Disease (January 2019), though it is not yet FDA cleared or CE-marked, and has been granted patents in the US, Australia, and Japan covering the methodology and system architecture.

The company monetizes through three primary channels: (1) software licensing to neurologists, psychiatrists, and clinical sites who prescribe the patient download, (2) contract-based pharma/biotech clinical-trial services for neurologic and psychiatric drug development, and (3) regional revenue-sharing or licensing via channel partners — bioaccess for Latin America and N-Strategy Consulting Services for Asia-Pacific. Pricing is enterprise-negotiated and not publicly disclosed. Research validation is conducted with a global network of academic institutions including Boston University, Karolinska Institutet, Huntington Center Ulm, UCSF, Mayo Clinic, Lund University, Uppsala University, University of Toronto, Dutch University Medical Centers, and others.

NeuraMetrix firmographics

Firmographics
Name
NeuraMetrix
Legal name
NeuraMetrix, Inc.
Website
https://neurametrix.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
NeuraMetrix is a private medical device company that has developed a passive digital biomarker platform measuring typing cadence on a personal computer to detect and monitor neurological diseases and psychiatric disorders, serving physicians, patients, pharmaceutical trial sponsors, and academic researchers; it holds FDA Breakthrough Device designation for Parkinson's Disease.
Ownership category
akta.pro rank

NeuraMetrix industry classification

Industry
Product category
Digital Health / Digital Biomarker Software
NAICS
Other Computer Related Services (541519)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Digital biomarker software
  • Typing cadence analysis
  • Neurological disease monitoring
  • Cognitive function assessment
  • Passive brain health tracking

Where NeuraMetrix is headquartered

Location

Headquarters

HQ city
Asheville
HQ country
United States
HQ region
North America

Offices4 records

Markets served

NeuraMetrix business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Clinical Software Licensing (Physician/Clinic): NeuraMetrix TC software is prescribed/distributed by physicians and clinical trial teams to patients. The physician provides the software download link via email. The company generates revenue through software licensing to healthcare providers and clinical trial operators. Pricing is not publicly disclosed; billing is likely per-seat or subscription-based per patient or per physician/clinic.
  2. Pharma Drug Trial Services: NeuraMetrix provides its digital biomarker for use in pharmaceutical clinical trials for neurological and psychiatric drug development. Pharma companies use the platform to monitor trial participants' cognitive and motor performance, enabling faster go/no-go decisions, reduced heterogeneity, and fewer dropouts. Revenue likely derived from study setup fees, per-subject licensing, and data analysis services.
  3. Regional Distribution Partnerships: NeuraMetrix partners with regional distributors (bioaccess™ for Latin America, NSCS for Asia-Pacific) who commercialize the technology in their respective markets, likely through revenue-sharing or licensing arrangements.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

NeuraMetrix product offering

Product offering

Core offering

NeuraMetrix provides the NeuraMetrix TC platform, a passive digital biomarker that detects and monitors neurological diseases and psychiatric disorders by analyzing typing cadence (keystroke dwell and flight times) on a patient's own Windows PC or laptop. The platform comprises three components: the NeuraMetrix TC Application (passive client), the NeuraMetrix Server (cloud analytics computing the proprietary SINCOR inconsistency metric), and the NeuraMetrix Online Dashboard (visualization portal for clinicians and patients). It is sold primarily through physicians/clinics and clinical trial operators for remote, continuous brain health monitoring.

Product overview

NeuraMetrix offers a unified digital biomarker platform consisting of three integrated components: the NeuraMetrix TC Application (a passive desktop client for keystroke data collection), the NeuraMetrix Server (cloud-based analysis infrastructure running proprietary SINCOR algorithms), and the NeuraMetrix Online Dashboard (a web portal for clinicians, researchers, and patients to visualize inconsistency scores and disease progression trends). The platform measures typing cadence inconsistency as a digital biomarker for detecting and monitoring neurodegenerative diseases (Parkinson's, Huntington's, Alzheimer's) and psychiatric disorders (depression, bipolar disorder).

Differentiator

Problem solved

Functional benefit

Products and services

  • NeuraMetrix TC Application Passive desktop client software that runs in the background on a user's Windows PC or laptop, collecting keystroke timing data (dwell and flight times) whenever the keyboard is used. The software is downloaded via email link sent by a physician or clinical trial team, requires no active participation, and never stores typed content — only timing metadata.
  • NeuraMetrix Server Secure cloud-based server infrastructure that receives typing cadence data batches from the TC Application, performs outlier analysis, and computes the proprietary SINCOR (inconsistency) metric using patented algorithms.
  • NeuraMetrix Online Dashboard Web portal (portal.neurametrix.com) that visualizes the patient's SINCOR inconsistency score as a longitudinal line graph for healthcare providers, research institutions, and (when permitted) patients, enabling monitoring of brain health trends over time.

Quantifiable outcome

  • 65 million data points collected and analyzed in a single study (154 subjects, 90 days)
  • +4 more outcomes

Companies that use NeuraMetrix

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles3 records

NeuraMetrix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

NeuraMetrix partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • Boston University School of MedicineflagshipStrategic or Co-development Partner · 15 April 2021Boston University School of Medicine selected NeuraMetrix's digital biomarker to participate in the Precision Brain Health Initiative, funded by the American Heart Association in collaboration with global philanthropist Bill Gates. NeuraMetrix is one of the selected technologies in this major brain health program. Active research programs include heart problems and dementia, with planned Alzheimer's studies.
  • Huntington Center Ulm, Ulm University, GermanyflagshipStrategic or Co-development Partner · 8 April 2021NeuraMetrix and Huntington Center Ulm (Department of Neurology, Ulm University, Germany) jointly published a peer-reviewed research article: 'Monitoring the Phenotype in Huntington Disease by Analysis of Keyboard Typing During Real Life Computer Use' in the Journal of Huntington's Disease. The study demonstrated that the digital biomarker can separate Huntington's mutation carriers with no visible symptoms into two groups: disease-not-yet-active and disease-has-already-begun.
  • bioaccess™coreChannel Partner/ Reseller/ Distributor · 27 January 2021Orlando-based contract research organization (CRO) and market access consulting firm dedicated to helping innovative Medtech companies succeed with market expansion in Latin America. bioaccess™ and NeuraMetrix entered a partnership agreement to conduct clinical research and commercialize the digital brain health monitoring biomarker based on typing cadence in Latin America. This is a key channel partnership for NeuraMetrix to reach patients and healthcare providers in Latin American markets including Colombia.
  • N-Strategy Consulting Services (NSCS)coreChannel Partner/ Reseller/ Distributor · 23 July 2019NSCS, founded by Nathanael Noiraud, with its founder and CEO, accelerates and invests in NeuraMetrix's Asia-Pacific market entry. NSCS provides market entry strategy, business development, and investment to establish NeuraMetrix in Malaysia and other Asia-Pacific markets.
  • McKinsey & Company (J.P. Morgan Healthcare Conference)minorGTM or Marketing Partner · 8 January 2019NeuraMetrix showcased its technology at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, where the FDA Breakthrough Device designation was announced. The company has also been selected to present at McKinsey's Early-Stage Investor Conference (ESIC) in June 2022.
  • SharpBrains (Brainnovations Competition)minorGTM or Marketing Partner · 9 January 2018NeuraMetrix won the SharpBrains Brainnovations competition (January 2018) for its innovative digital biomarker technology. The competition win provided visibility and recognition in the digital brain health ecosystem.
  • Michael J. Fox Foundation (Fox Trial Finder)flagshipStrategic or Co-development PartnerNeuraMetrix completed a landmark study with the Michael J. Fox Foundation's Fox Trial Finder program. 154 subjects were monitored for 90 days, collecting and analyzing 65 million data points. The study demonstrated the ability to distinguish diagnosed Parkinson's patients from healthy subjects and monitor disease progression, identifying patients whose variability was under control, out of control, and worsening.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

NeuraMetrix competitors and assessment

Company assessment

Direct peers

  • Altoida: Digital biomarker platform that uses cognitive and motor tasks on smartphones/tablets to predict and diagnose Alzheimer's and MCI. Directly comparable to NeuraMetrix as a digital neurological biomarker seeking FDA pathway and pharma trial adoption.
  • Cambridge Cognition: Provider of computerized cognitive assessments (e.g., CANTAB) widely used in pharma clinical trials and clinical research for neurological and psychiatric conditions. Comparable in serving pharma CNS trial sponsors with objective cognitive endpoints.
  • Cumulus Neuroscience: Digital biomarker company building a multi-modal at-home neurology platform for CNS clinical trials and clinical practice across conditions like depression and Alzheimer's. Closely comparable in modality (passive/remote measurement) and pharma trial positioning.
  • BrainCheck: Digital cognitive assessment platform used by physicians and clinical researchers to detect and monitor cognitive impairment. Overlaps with NeuraMetrix in clinical decision support for neurology and in clinician-driven workflows.

Emerging players

  • Linus Health: Digital cognitive health company focused on early detection of dementia and other neurological conditions via tablet-based assessments. Adjacent emerging competitor targeting similar early-detection use cases in neurology practices.

Broad incumbents

  • Evidation Health: Large-scale digital health measurement platform that captures continuous behavioral and physiological data from consented consumers for research and pharma. Comparable in mining passive digital signals for health insights, though broader in scope.
  • Akili Interactive: Public digital therapeutics company with FDA-cleared products for ADHD and other cognitive conditions. Comparable in pursuing prescription digital products for CNS indications, but delivers active treatment rather than passive monitoring.
  • Clario (formerly Bioclinica): Major clinical trial technology and imaging/biomarker vendor serving pharma CNS trials at scale. Comparable as a vendor competing for pharma digital-endpoint budgets, though with a much broader portfolio including imaging and eCOA.
  • Roche / Genentech (Floodlight): Major pharma with Floodlight, a smartphone-based passive digital biomarker program for MS and other neurological diseases. Represents the kind of vertically integrated, well-capitalized competitor that can bundle digital biomarkers into its own drug commercialization.
  • Medidata (Dassault Systèmes): Dominant clinical trial technology platform with expanding digital biomarker and sensor capabilities acquired through its ecosystem. Comparable as a platform-of-record for CNS pharma trials where NeuraMetrix seeks to be embedded.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

NeuraMetrix social profiles

Digital presence

NeuraMetrix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuraMetrix leadership team

Management profile

Number of profiles

Profiles5 records

NeuraMetrix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuraMetrix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuraMetrix

What does NeuraMetrix do?

NeuraMetrix provides the NeuraMetrix TC platform, a passive digital biomarker that detects and monitors neurological diseases and psychiatric disorders by analyzing typing cadence (keystroke dwell and flight times) on a patient's own Windows PC or laptop. The platform comprises three components: the NeuraMetrix TC Application (passive client), the NeuraMetrix Server (cloud analytics computing the proprietary SINCOR inconsistency metric), and the NeuraMetrix Online Dashboard (visualization portal for clinicians and patients). It is sold primarily through physicians/clinics and clinical trial operators for remote, continuous brain health monitoring.

Is NeuraMetrix a public or private company?

NeuraMetrix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeuraMetrix founded?

NeuraMetrix was founded in 2017. It employs 1 to 10 people.

Where is NeuraMetrix based?

NeuraMetrix is headquartered in Asheville, United States, in the North America region.

How does NeuraMetrix make money?

Three revenue lines are on record. Clinical Software Licensing (Physician/Clinic) is the primary driver. The others are pharma Drug Trial Services and regional Distribution Partnerships.

Who are NeuraMetrix's main competitors?

Direct peers on record are Altoida, Cambridge Cognition, Cumulus Neuroscience and BrainCheck. Linus Health is listed as an emerging player. Broad incumbents are Evidation Health, Akili Interactive, Clario (formerly Bioclinica), Roche / Genentech (Floodlight) and Medidata (Dassault Systèmes).

Does NeuraMetrix have an API?

No public API is recorded for NeuraMetrix.

What industry is NeuraMetrix in?

NeuraMetrix's product category is Digital Health / Digital Biomarker Software. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring). Its NAICS code is 541519 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDigital Neuro Biomarkers Market Research 2025-2030, Competitive Analysis of Altoida, Koneksa, Biogen, Roche, NeuraMetrix, Merck, Linus Health, Neurotrack Technologies, Huma, and NeuraLightThe global digital neuro biomarkers market is projected to reach USD 2.82 billion by 2030, growing at a 25.7% CAGR from 2025 to 2030. Wearable devices held the largest segment share at 39.9% in 2024, and North America led with 37.7% of revenue. Growth is driven by rising neurological disorders and AI integration.NetcapitalNeuraMetrix ← NetcapitalNeuraMetrix is a startup focused on developing a remote monitoring tool that uses typing cadence to detect and monitor neurological diseases, including Alzheimer’s and Parkinson’s. The startup currently markets its technology to pharmaceutical companies and research institutions such as Boston University and Harvard, with plans to expand to hospitals and potential consumers. The company emphasizes the significance of accurate measurements in treating neurological disorders, supported by 7 patents for their technology.IEEE SpectrumTech Watches You for Digital Symptoms of Brain DisordersThree startups—Mindstrong Health, NeuraMetrix, and WinterLight Labs—use digital data from typing, speech, and smartphone use to detect brain disorders. Mindstrong's app is used in trials for schizophrenia and depression, while NeuraMetrix claims 99.9% accuracy for Parkinson's, and WinterLight targets Alzheimer's monitoring.